^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Hodgkin Lymphoma
    Drug:Rituxan (rituximab) (CD20 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Published date:
    04/08/2022
    Excerpt:
    Pediatric Hodgkin Lymphoma…Primary Systemic Therapy…CVbP ± Rituximab…
    Secondary therapy:
    CVbP
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    12/14/2020
    Excerpt:
    Hodgkin Lymphoma: NLPHL, second-line options added:…R-Bendamustine...
    Secondary therapy:
    bendamustine
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Excerpt:
    Hodgkin Lymphoma...PRINCIPLES OF SYSTEMIC THERAPY...R + ICE
    Secondary therapy:
    ICE
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Excerpt:
    Rituximab should be considered with all second-line chemotherapy regimens for patients with relapsed or refractory NLPHL.